A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

BACKGROUND: Triweekly capecitabine plus irinotecan (XELIRI) is not completely regarded as a valid substitute for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. We conducted a phase I/II study to assess the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Matsusaka, Satoshi, Shinozaki, Eiji, Ozaka, Masato, Ogura, Mariko, Chin, Keisho, Yamaguchi, Toshiharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365742/
https://www.ncbi.nlm.nih.gov/pubmed/25834402
http://dx.doi.org/10.2147/DDDT.S80449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365742/
https://www.ncbi.nlm.nih.gov/pubmed/25834402
http://dx.doi.org/10.2147/DDDT.S80449

Ejemplares similares